VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q56424260 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000042.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q56424260‏
024 ‎‡a 0000-0001-5773-8733‏ ‎‡2 orcid‏
024 ‎‡a 7401813822‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q56424260‏
100 0 ‎‡a Jonathan K Ball‏ ‎‡9 ast‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a জোনাথন বল‏ ‎‡9 bn‏
400 0 ‎‡a Jonathan Ball‏ ‎‡c British virologist‏ ‎‡9 en‏
400 0 ‎‡a Jonathan K Ball‏ ‎‡c virólogo británico‏ ‎‡9 es‏
400 0 ‎‡a Jonathan K Ball‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine.‏
670 ‎‡a Author's A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.‏
670 ‎‡a Author's A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo‏
670 ‎‡a Author's A polymerase chain reaction method for the amplification of full-length envelope genes of HIV-1 from DNA samples containing single molecules of HIV-1 provirus‏
670 ‎‡a Author's An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission‏
670 ‎‡a Author's An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule‏
670 ‎‡a Author's Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution‏
670 ‎‡a Author's Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets‏
670 ‎‡a Author's Association of antibodies to hepatitis C virus glycoproteins 1 and 2‏
670 ‎‡a Author's Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.‏
670 ‎‡a Author's B-cell receptors expressed by lymphomas of hepatitis C virus‏
670 ‎‡a Author's B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins‏
670 ‎‡a Author's Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin‏
670 ‎‡a Author's Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge‏
670 ‎‡a Author's Challenges on the development of a pseudotyping assay for Zika glycoproteins‏
670 ‎‡a Author's Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus‏
670 ‎‡a Author's Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.‏
670 ‎‡a Author's Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin‏
670 ‎‡a Author's Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3‏
670 ‎‡a Author's Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3 (V3) envelope sequences in cases where semen populations are distinct from those present in blood‏
670 ‎‡a Author's Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine‏
670 ‎‡a Author's Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine (AZT) therapy.‏
670 ‎‡a Author's Coronavirus (CoV) proteins in GtoPdb v.2022.2‏
670 ‎‡a Author's Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes‏
670 ‎‡a Author's Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies‏
670 ‎‡a Author's Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8‏
670 ‎‡a Author's Detection of HIV-1 by digoxigenin-labelled PCR and microtitre plate solution hybridisation assay and prevention of PCR carry-over by uracil-N-glycosylase‏
670 ‎‡a Author's Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.‏
670 ‎‡a Author's Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.‏
670 ‎‡a Author's Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.‏
670 ‎‡a Author's Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA.‏
670 ‎‡a Author's Discovery of Novel Alphacoronaviruses in European Rodents and Shrews‏
670 ‎‡a Author's Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation‏
670 ‎‡a Author's Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection.‏
670 ‎‡a Author's Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity‏
670 ‎‡a Author's Flexible and rapid construction of viral chimeras applied to hepatitis C virus.‏
670 ‎‡a Author's Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.‏
670 ‎‡a Author's Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.‏
670 ‎‡a Author's Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host‏
670 ‎‡a Author's Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes‏
670 ‎‡a Author's Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals‏
670 ‎‡a Author's HIV-1 co-receptor expression and epithelial immune cells of the cervix in asymptomatic women attending a genitourinary medicine clinic.‏
670 ‎‡a Author's HIV coreceptor and chemokine ligand gene expression in the male urethra and female cervix.‏
670 ‎‡a Author's Human Adaptation of Ebola Virus during the West African Outbreak‏
670 ‎‡a Author's Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus‏
670 ‎‡a Author's Human parainfluenza 2 & 4: Clinical and genetic epidemiology in the UK, 2013–2017, reveals distinct disease features and co‐circulating genomic subtypes‏
670 ‎‡a Author's Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding‏
670 ‎‡a Author's Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2‏
670 ‎‡a Author's Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors‏
670 ‎‡a Author's Long-lasting viability of HIV after patient's death.‏
670 ‎‡a Author's Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein‏
670 ‎‡a Author's Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization‏
670 ‎‡a Author's Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step‏
670 ‎‡a Author's Non-ionic detergents facilitate non-specific binding of M13 bacteriophage to polystyrene surfaces.‏
670 ‎‡a Author's Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis.‏
670 ‎‡a Author's Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.‏
670 ‎‡a Author's Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.‏
670 ‎‡a Author's Polymer microarrays rapidly identify competitive adsorbents of virus-like particles‏
670 ‎‡a Author's Production of single-stranded DNA using a uracil-N-glycosylase-mediated asymmetric polymerase chain reaction method‏
670 ‎‡a Author's Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.‏
670 ‎‡a Author's SARS-CoV-2 proteins (version 2020.2) in the IUPHAR/BPS Guide to Pharmacology Database‏
670 ‎‡a Author's Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex‏
670 ‎‡a Author's Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.‏
670 ‎‡a Author's Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.‏
670 ‎‡a Author's Tagged polymerase chain reaction subtractive hybridization for the enrichment of phage display random peptide libraries.‏
670 ‎‡a Author's Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice‏
670 ‎‡a Author's The past, present and future of neutralizing antibodies for hepatitis C virus‏
670 ‎‡a Author's The role of humoral innate immunity in hepatitis C virus infection.‏
670 ‎‡a Author's The role of neutralizing antibodies in hepatitis C virus infection.‏
670 ‎‡a Author's The use of uracil-N-glycosylase in the preparation of PCR products for direct sequencing.‏
670 ‎‡a Author's TT virus sequence heterogeneity in vivo: evidence for co-infection with multiple genetic types.‏
670 ‎‡a Author's Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies‏
670 ‎‡a Author's Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.‏
670 ‎‡a Author's Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis‏
670 ‎‡a wikidata authority control‏ ‎‡u https://viaf.org/processed/ISNI|0000000134413565‏
670 ‎‡a wikidata site links‏ ‎‡u https://en.wikipedia.org/wiki/Jonathan_Ball_(virologist)‏
670 ‎‡a wikidata site links‏ ‎‡u https://es.wikipedia.org/wiki/Jonathan_Ball_(virólogo)‏
909 ‎‡a (scopus) 7401813822‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000157738733‏ ‎‡9 1‏
919 ‎‡a longlastingviabilityofhivafterpatientsdeath‏ ‎‡A Long-lasting viability of HIV after patient's death.‏ ‎‡9 1‏
919 ‎‡a naturallyoccurringantibodiesthatrecognizelinearepitopesintheaminoterminusofthehepatitis100viruse2proteinconfernoninterferingadditiveneutralization‏ ‎‡A Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization‏ ‎‡9 1‏
919 ‎‡a neutralizingmonoclonalantibodiesagainsthepatitis100viruse2proteinbinddiscontinuousepitopesandinhibitinfectionatapostattachmentstep‏ ‎‡A Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step‏ ‎‡9 1‏
919 ‎‡a nonionicdetergentsfacilitatenonspecificbindingofm13bacteriophagetopolystyrenesurfaces‏ ‎‡A Non-ionic detergents facilitate non-specific binding of M13 bacteriophage to polystyrene surfaces.‏ ‎‡9 1‏
919 ‎‡a nonmacrophagetropichumanimmunodeficiencyvirustype1r5envelopespredominateinbloodlymphnodesandsemenimplicationsfortransmissionandpathogenesis‏ ‎‡A Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis.‏ ‎‡9 1‏
919 ‎‡a novelfunctionalhepatitis100virusglycoproteinisolatesidentifiedusinganoptimizedviralpseudotypeentryassay‏ ‎‡A Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.‏ ‎‡9 1‏
919 ‎‡a novelhumananticlaudin1mabsinhibithepatitis100virusinfectionandmaysynergizewithantisrb1mab‏ ‎‡A Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.‏ ‎‡9 1‏
919 ‎‡a polymermicroarraysrapidlyidentifycompetitiveadsorbentsofviruslikeparticles‏ ‎‡A Polymer microarrays rapidly identify competitive adsorbents of virus-like particles‏ ‎‡9 1‏
919 ‎‡a productionofsinglestrandeddnausingauracilnglycosylasemediatedasymmetricpolymerasechainreactionmethod‏ ‎‡A Production of single-stranded DNA using a uracil-N-glycosylase-mediated asymmetric polymerase chain reaction method‏ ‎‡9 1‏
919 ‎‡a recombinanthuman50ficolindirectlyneutralizeshepatitis100virusentry‏ ‎‡A Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.‏ ‎‡9 1‏
919 ‎‡a sarscov2proteinsversion20202intheiupharbpsguidetopharmacologydatabase‏ ‎‡A SARS-CoV-2 proteins (version 2020.2) in the IUPHAR/BPS Guide to Pharmacology Database‏ ‎‡9 1‏
919 ‎‡a severefibrosisinhepatitis100virusinfectedpatientsisassociatedwithincreasedactivityofthemannanbindinglectinmblmblassociatedserineprotease1masp1complex‏ ‎‡A Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex‏ ‎‡9 1‏
919 ‎‡a specificinteractionofhepatitis100virusglycoproteinswithmannanbindinglectininhibitsvirusentry‏ ‎‡A Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.‏ ‎‡9 1‏
919 ‎‡a structuralflexibilityofaconservedantigenicregioninhepatitis100virusglycoproteine2recognizedbybroadlyneutralizingantibodies‏ ‎‡A Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.‏ ‎‡9 1‏
919 ‎‡a taggedpolymerasechainreactionsubtractivehybridizationfortheenrichmentofphagedisplayrandompeptidelibraries‏ ‎‡A Tagged polymerase chain reaction subtractive hybridization for the enrichment of phage display random peptide libraries.‏ ‎‡9 1‏
919 ‎‡a targetingahostcellentryfactorbarricadesantiviralresistanthcvvariantsfromontherapybreakthroughinhumanlivermice‏ ‎‡A Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice‏ ‎‡9 1‏
919 ‎‡a pastpresentandfutureofneutralizingantibodiesforhepatitis100virus‏ ‎‡A The past, present and future of neutralizing antibodies for hepatitis C virus‏ ‎‡9 1‏
919 ‎‡a roleofhumoralinnateimmunityinhepatitis100virusinfection‏ ‎‡A The role of humoral innate immunity in hepatitis C virus infection.‏ ‎‡9 1‏
919 ‎‡a roleofneutralizingantibodiesinhepatitis100virusinfection‏ ‎‡A The role of neutralizing antibodies in hepatitis C virus infection.‏ ‎‡9 1‏
919 ‎‡a useofuracilnglycosylaseinthepreparationofpcrproductsfordirectsequencing‏ ‎‡A The use of uracil-N-glycosylase in the preparation of PCR products for direct sequencing.‏ ‎‡9 1‏
919 ‎‡a ttvirussequenceheterogeneityinvivoevidenceforcoinfectionwithmultiplegenetictypes‏ ‎‡A TT virus sequence heterogeneity in vivo: evidence for co-infection with multiple genetic types.‏ ‎‡9 1‏
919 ‎‡a useofshorttandemrepeatfingerprintingtovalidatesampleoriginsinhepatitis100virusmolecularepidemiologystudies‏ ‎‡A Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies‏ ‎‡9 1‏
919 ‎‡a variationinhiv1r5macrophagetropismcorrelateswithsensitivitytoreagentsthatblockenvelopecd4interactionsbutnotwithsensitivitytootherentryinhibitors‏ ‎‡A Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.‏ ‎‡9 1‏
919 ‎‡a variationinthebiologicalpropertiesofhiv1r5envelopesimplicationsofenvelopestructuretransmissionandpathogenesis‏ ‎‡A Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis‏ ‎‡9 1‏
919 ‎‡a intercompartmentalrecombinationofhiv1contributestoenvintrahostdiversityandmodulatesviraltropismandsensitivitytoentryinhibitors‏ ‎‡A Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors‏ ‎‡9 1‏
919 ‎‡a identificationofnewfunctionalregionsinhepatitis100virusenvelopeglycoproteine2‏ ‎‡A Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2‏ ‎‡9 1‏
919 ‎‡a identificationofconservedresiduesinthee2envelopeglycoproteinofthehepatitis100virusthatarecriticalforcd81binding‏ ‎‡A Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding‏ ‎‡9 1‏
919 ‎‡a humanparainfluenza2and4clinicalandgeneticepidemiologyintheuk20132017revealsdistinctdiseasefeaturesandcocirculatinggenomicsubtypes‏ ‎‡A Human parainfluenza 2 & 4: Clinical and genetic epidemiology in the UK, 2013–2017, reveals distinct disease features and co‐circulating genomic subtypes‏ ‎‡9 1‏
919 ‎‡a humancombinatoriallibrariesyieldrareantibodiesthatbroadlyneutralizehepatitis100virus‏ ‎‡A Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus‏ ‎‡9 1‏
919 ‎‡a humanadaptationofebolavirusduringthewestafricanoutbreak‏ ‎‡A Human Adaptation of Ebola Virus during the West African Outbreak‏ ‎‡9 1‏
919 ‎‡a hivcoreceptorandchemokineligandgeneexpressioninthemaleurethraandfemalecervix‏ ‎‡A HIV coreceptor and chemokine ligand gene expression in the male urethra and female cervix.‏ ‎‡9 1‏
919 ‎‡a hiv1coreceptorexpressionandepithelialimmunecellsofthecervixinasymptomaticwomenattendingagenitourinarymedicineclinic‏ ‎‡A HIV-1 co-receptor expression and epithelial immune cells of the cervix in asymptomatic women attending a genitourinary medicine clinic.‏ ‎‡9 1‏
919 ‎‡a hepatitis100virusquasispeciesandpseudotypeanalysisfromacuteinfectiontochronicityinhiv1coinfectedindividuals‏ ‎‡A Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals‏ ‎‡9 1‏
919 ‎‡a hepatitis100virushcvinfectionmayelicitneutralizingantibodiestargetingepitopesconservedinallviralgenotypes‏ ‎‡A Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes‏ ‎‡9 1‏
919 ‎‡a hepatitis100virusenvelopeglycoproteinfitnessdefinesviruspopulationcompositionfollowingtransmissiontoanewhost‏ ‎‡A Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host‏ ‎‡9 1‏
919 ‎‡a hepatitis100patientderivedglycoproteinsexhibitmarkeddifferencesinsusceptibilitytoserumneutralizingantibodiesgeneticsubtypedefinesantigenicbutnotneutralizationserotype‏ ‎‡A Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.‏ ‎‡9 1‏
919 ‎‡a genomicvariationofhumanimmunodeficiencyvirustype1hiv1molecularanalysesofhiv1insequentialbloodsamplesandvariousorgansobtainedatautopsy‏ ‎‡A Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.‏ ‎‡9 1‏
919 ‎‡a flexibleandrapidconstructionofviralchimerasappliedtohepatitis100virus‏ ‎‡A Flexible and rapid construction of viral chimeras applied to hepatitis C virus.‏ ‎‡9 1‏
919 ‎‡a evolutionarytrendsofthe1hypervariableregionofthehepatitis100viruse2proteininindividualswithdifferingliverdiseaseseverity‏ ‎‡A Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity‏ ‎‡9 1‏
919 ‎‡a evolutionarydynamicsofhepatitis100virusenvelopegenesduringchronicinfection‏ ‎‡A Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection.‏ ‎‡9 1‏
919 ‎‡a dramaticpotentiationoftheantiviralactivityofhivantibodiesbycholesterolconjugation‏ ‎‡A Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation‏ ‎‡9 1‏
919 ‎‡a discoveryofnovelalphacoronavirusesineuropeanrodentsandshrews‏ ‎‡A Discovery of Novel Alphacoronaviruses in European Rodents and Shrews‏ ‎‡9 1‏
919 ‎‡a developmentofastrandspecificrtpcrbasedassaytodetectthereplicativeformofhepatitis100virusrna‏ ‎‡A Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA.‏ ‎‡9 1‏
919 ‎‡a developmentofahighthroughputpyrosequencingassayformonitoringtemporalevolutionandresistanceassociatedvariantemergenceinthehepatitis100virusproteasecodingregion‏ ‎‡A Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.‏ ‎‡9 1‏
919 ‎‡a developmentandcharacterizationofahumanmonoclonalantibodytargetingthenterminalregionofhepatitis100virusenvelopeglycoproteine1‏ ‎‡A Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.‏ ‎‡9 1‏
919 ‎‡a determinationofthehumanantibodyresponsetotheepitopedefinedbythehepatitis100virusneutralizingmonoclonalantibodyap33‏ ‎‡A Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.‏ ‎‡9 1‏
919 ‎‡a detectionofhiv1bydigoxigeninlabelledpcrandmicrotitreplatesolutionhybridisationassayandpreventionofpcrcarryoverbyuracilnglycosylase‏ ‎‡A Detection of HIV-1 by digoxigenin-labelled PCR and microtitre plate solution hybridisation assay and prevention of PCR carry-over by uracil-N-glycosylase‏ ‎‡9 1‏
919 ‎‡a dendriticcellsculturedfrommononuclearcellsandcd34cellsinmyelomadonotharbourhumanherpesvirus8‏ ‎‡A Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8‏ ‎‡9 1‏
919 ‎‡a definitionofaconservedimmunodominantdomainonhepatitis100viruse2glycoproteinbyneutralizinghumanmonoclonalantibodies‏ ‎‡A Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies‏ ‎‡9 1‏
919 ‎‡a crossgenotypecharacterizationofgeneticdiversityandmolecularadaptationinhepatitis100virusenvelopeglycoproteingenes‏ ‎‡A Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes‏ ‎‡9 1‏
919 ‎‡a coronaviruscovproteinsingtopdbvol20222‏ ‎‡A Coronavirus (CoV) proteins in GtoPdb v.2022.2‏ ‎‡9 1‏
919 ‎‡a concurrentevolutionofregionsoftheenvelopeandpolymerasegenesofhumanimmunodeficiencyvirustype1duringzidovudineazttherapy‏ ‎‡A Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine (AZT) therapy.‏ ‎‡9 1‏
919 ‎‡a concurrentevolutionofregionsoftheenvelopeandpolymerasegenesofhumanimmunodeficiencyvirustype1duringzidovudine‏ ‎‡A Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 during zidovudine‏ ‎‡9 1‏
919 ‎‡a monoclonalantibodyap33definesabroadlyneutralizingepitopeonthehepatitis100viruse2envelopeglycoprotein‏ ‎‡A Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein‏ ‎‡9 1‏
919 ‎‡a concordancebetweensemenderivedhiv1proviraldnaandviralrnahypervariableregion3v3envelopesequencesincaseswheresemenpopulationsaredistinctfromthosepresentinblood‏ ‎‡A Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3 (V3) envelope sequences in cases where semen populations are distinct from those present in blood‏ ‎‡9 1‏
919 ‎‡a concordancebetweensemenderivedhiv1proviraldnaandviralrnahypervariableregion3‏ ‎‡A Concordance between semen-derived HIV-1 proviral DNA and viral RNA hypervariable region 3‏ ‎‡9 1‏
919 ‎‡a cholesterolconjugationpotentiatestheantiviralactivityofanhivimmunoadhesin‏ ‎‡A Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin‏ ‎‡9 1‏
919 ‎‡a characterizationofthehepatitis100viruse2epitopedefinedbythebroadlyneutralizingmonoclonalantibodyap33‏ ‎‡A Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.‏ ‎‡9 1‏
919 ‎‡a characterizationofhostrangeandcellentrypropertiesofthemajorgenotypesandsubtypesofhepatitis100virus‏ ‎‡A Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus‏ ‎‡9 1‏
919 ‎‡a challengesonthedevelopmentofapseudotypingassayforzikaglycoproteins‏ ‎‡A Challenges on the development of a pseudotyping assay for Zika glycoproteins‏ ‎‡9 1‏
919 ‎‡a broadlyneutralizingantibodiesprotectagainsthepatitis100virusquasispecieschallenge‏ ‎‡A Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge‏ ‎‡9 1‏
919 ‎‡a broadneutralizationofhepatitis100virusresistantvariantsbycivacirhepatitis100immunoglobulin‏ ‎‡A Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin‏ ‎‡9 1‏
919 ‎‡a bcellreceptorsexpressedbylymphomasofhepatitis100virushcvinfectedpatientsrarelyreactwiththeviralproteins‏ ‎‡A B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins‏ ‎‡9 1‏
919 ‎‡a bcellreceptorsexpressedbylymphomasofhepatitis100virus‏ ‎‡A B-cell receptors expressed by lymphomas of hepatitis C virus‏ ‎‡9 1‏
919 ‎‡a associationofantibodiestohepatitis100virusglycoproteins1and2antie1e2withhcvdisease‏ ‎‡A Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.‏ ‎‡9 1‏
919 ‎‡a associationofantibodiestohepatitis100virusglycoproteins1and2‏ ‎‡A Association of antibodies to hepatitis C virus glycoproteins 1 and 2‏ ‎‡9 1‏
919 ‎‡a analysisofthebindingofhepatitis100virusgenotype1aand1be2glycoproteinstoperipheralbloodmononuclearcellsubsets‏ ‎‡A Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets‏ ‎‡9 1‏
919 ‎‡a analysisofserinecodonconservationrevealsdiversephenotypicconstraintsonhepatitis100virusglycoproteinevolution‏ ‎‡A Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution‏ ‎‡9 1‏
919 ‎‡a ancestralhostdefencepeptidewithinhumanβdefensin3recapitulatestheantibacterialandantiviralactivityofthefulllengthmolecule‏ ‎‡A An ancestral host defence peptide within human β-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule‏ ‎‡9 1‏
919 ‎‡a alpacananobodyinhibitshepatitis100virusentryandcelltocelltransmission‏ ‎‡A An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission‏ ‎‡9 1‏
919 ‎‡a polymerasechainreactionmethodfortheamplificationoffulllengthenvelopegenesofhiv1fromdnasamplescontainingsinglemoleculesofhiv1provirus‏ ‎‡A A polymerase chain reaction method for the amplification of full-length envelope genes of HIV-1 from DNA samples containing single molecules of HIV-1 provirus‏ ‎‡9 1‏
919 ‎‡a novelneutralizinghumanmonoclonalantibodybroadlyabrogateshepatitis100virusinfectioninvitroandinvivo‏ ‎‡A A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo‏ ‎‡9 1‏
919 ‎‡a diversepanelofhepatitis100virusglycoproteinsforuseinvaccineresearchrevealsextremesofmonoclonalantibodyneutralizationresistance‏ ‎‡A A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.‏ ‎‡9 1‏
919 ‎‡a caseofhepatitis100virustransmissionacquiredthroughsharingahaemodialysismachine‏ ‎‡A A case of hepatitis C virus transmission acquired through sharing a haemodialysis machine.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000035019554‏
996 ‎‡2 CAOONL|ncf10510890‏
996 ‎‡2 J9U|987007446500305171‏
996 ‎‡2 LC|no 95030674‏
996 ‎‡2 BIBSYS|10072660‏
996 ‎‡2 SUDOC|22477865X‏
996 ‎‡2 LC|n 82102031‏
996 ‎‡2 LC|no2004095682‏
996 ‎‡2 ISNI|0000000067638296‏
996 ‎‡2 LC|n 2017072768‏
996 ‎‡2 SUDOC|193298082‏
996 ‎‡2 NTA|128325712‏
996 ‎‡2 LC|nr 93024393‏
996 ‎‡2 LC|n 50017235‏
996 ‎‡2 NLA|000035648210‏
996 ‎‡2 RERO|A002963733‏
996 ‎‡2 RERO|A002963730‏
996 ‎‡2 ISNI|0000000004770548‏
996 ‎‡2 LC|no2008101245‏
996 ‎‡2 N6I|vtls001095544‏
996 ‎‡2 LIH|LNB:B_m__q__t_;=C_e_‏
996 ‎‡2 LC|no2016062253‏
996 ‎‡2 NTA|290825601‏
996 ‎‡2 SUDOC|07332129X‏
996 ‎‡2 LC|no2021001196‏
996 ‎‡2 ISNI|0000000498718212‏
996 ‎‡2 PLWABN|9810672874805606‏
996 ‎‡2 LC|no 98077888‏
996 ‎‡2 J9U|987007273477305171‏
996 ‎‡2 ISNI|0000000080190465‏
996 ‎‡2 EGAXA|Balis125938123‏
996 ‎‡2 BIBSYS|1453362517077‏
996 ‎‡2 ISNI|0000000079806330‏
996 ‎‡2 NII|DA04168226‏
996 ‎‡2 ISNI|0000000078595236‏
996 ‎‡2 LC|n 86807876‏
996 ‎‡2 J9U|987007396502205171‏
996 ‎‡2 BIBSYS|90118651‏
996 ‎‡2 LC|no 97023665‏
996 ‎‡2 LC|no2013129199‏
996 ‎‡2 NTA|130786098‏
996 ‎‡2 ISNI|0000000024938061‏
996 ‎‡2 BNF|10796858‏
996 ‎‡2 ISNI|0000000025523941‏
996 ‎‡2 NUKAT|n 2011172214‏
996 ‎‡2 LC|n 83157222‏
996 ‎‡2 RERO|A022772603‏
996 ‎‡2 LC|n 2005028977‏
996 ‎‡2 ISNI|0000000062641867‏
996 ‎‡2 LC|n 80101062‏
996 ‎‡2 BIBSYS|4080365‏
996 ‎‡2 BIBSYS|1542227319754‏
996 ‎‡2 LC|no2013081869‏
996 ‎‡2 NUKAT|n 2009093508‏
996 ‎‡2 LC|n 88614628‏
996 ‎‡2 RERO|A020492578‏
996 ‎‡2 BNCHL|10000000000000000008474‏
996 ‎‡2 NTA|07175282X‏
996 ‎‡2 ISNI|0000000074238979‏
996 ‎‡2 BIBSYS|99026225‏
996 ‎‡2 NUKAT|n 2012161081‏
996 ‎‡2 BIBSYS|1682591865100‏
996 ‎‡2 LC|n 90674282‏
996 ‎‡2 ISNI|0000000073595878‏
996 ‎‡2 SUDOC|129716197‏
996 ‎‡2 BIBSYS|90510102‏
996 ‎‡2 LC|n 95042852‏
996 ‎‡2 J9U|987007383213805171‏
996 ‎‡2 DNB|1238541399‏
996 ‎‡2 ISNI|0000000054003064‏
996 ‎‡2 BIBSYS|2110063‏
996 ‎‡2 CAOONL|ncf10148376‏
996 ‎‡2 ISNI|0000000098618298‏
996 ‎‡2 LC|nr2005028818‏
996 ‎‡2 LC|n 89116396‏
996 ‎‡2 LC|no2004101009‏
996 ‎‡2 J9U|987007381451305171‏
996 ‎‡2 LC|n 92008383‏
996 ‎‡2 J9U|987007388583405171‏
996 ‎‡2 LNB|LNC10-000080928‏
996 ‎‡2 DNB|1246719886‏
996 ‎‡2 LC|n 2005171840‏
996 ‎‡2 ISNI|0000000025014135‏
996 ‎‡2 NII|DA10020988‏
996 ‎‡2 LC|n 88082058‏
996 ‎‡2 ISNI|0000000024309046‏
996 ‎‡2 CAOONL|ncf10539453‏
996 ‎‡2 J9U|987007369405905171‏
996 ‎‡2 LC|n 2004108286‏
996 ‎‡2 DNB|117561649‏
996 ‎‡2 NUKAT|n 00028148‏
996 ‎‡2 ISNI|0000000110565484‏
996 ‎‡2 LC|n 84141069‏
996 ‎‡2 DNB|1100938001‏
996 ‎‡2 BIBSYS|10043692‏
996 ‎‡2 SUDOC|16897469X‏
996 ‎‡2 LC|n 85146295‏
996 ‎‡2 N6I|vtls000006127‏
996 ‎‡2 BIBSYS|10043699‏
996 ‎‡2 LNB|LNC10-000054718‏
996 ‎‡2 RERO|A022820929‏
996 ‎‡2 LC|no2016039500‏
996 ‎‡2 LC|n 88088049‏
996 ‎‡2 RERO|A013657878‏
996 ‎‡2 LIH|LNB:BSQJ;=BM‏
996 ‎‡2 DE633|pe30012024‏
996 ‎‡2 LC|no2003032981‏
996 ‎‡2 DNB|120558343‏
996 ‎‡2 ISNI|0000000030875415‏
996 ‎‡2 NTA|130515906‏
996 ‎‡2 NKC|mzk2006355906‏
996 ‎‡2 LC|n 93122159‏
996 ‎‡2 NII|DA02464658‏
996 ‎‡2 LC|nb2014029278‏
996 ‎‡2 LC|nb2014029279‏
996 ‎‡2 CAOONL|ncf10174116‏
996 ‎‡2 ISNI|0000000030440817‏
996 ‎‡2 J9U|987010984235405171‏
996 ‎‡2 LC|nb2014029275‏
996 ‎‡2 LC|nb2014029276‏
996 ‎‡2 RERO|A022846123‏
996 ‎‡2 N6I|vtls000117900‏
996 ‎‡2 LC|no2018061348‏
996 ‎‡2 NDL|00519768‏
996 ‎‡2 PLWABN|9813915323605606‏
996 ‎‡2 NII|DA04107232‏
996 ‎‡2 CAOONL|ncf10192925‏
996 ‎‡2 DNB|1050677242‏
996 ‎‡2 N6I|vtls001208567‏
996 ‎‡2 BNF|12574026‏
996 ‎‡2 ISNI|0000000043266897‏
996 ‎‡2 NTA|339703067‏
996 ‎‡2 CAOONL|ncf10314695‏
996 ‎‡2 RERO|A002963725‏
996 ‎‡2 RERO|A002963726‏
996 ‎‡2 ISNI|0000000081342408‏
996 ‎‡2 ISNI|000000008446200X‏
996 ‎‡2 ISNI|0000000041656058‏
996 ‎‡2 CAOONL|ncf10186015‏
996 ‎‡2 BIBSYS|90295631‏
996 ‎‡2 ISNI|0000000114387259‏
996 ‎‡2 J9U|987007258008705171‏
996 ‎‡2 ISNI|0000000497294710‏
996 ‎‡2 ISNI|0000000391991366‏
996 ‎‡2 DNB|1074702042‏
996 ‎‡2 RERO|A027244298‏
996 ‎‡2 NUKAT|n 2012165214‏
996 ‎‡2 N6I|vtls002494529‏
996 ‎‡2 LC|n 2003033312‏
996 ‎‡2 LC|no2009136080‏
996 ‎‡2 J9U|987007310638505171‏
996 ‎‡2 N6I|vtls000061938‏
996 ‎‡2 LC|n 93804400‏
996 ‎‡2 DNB|143620487‏
996 ‎‡2 SUDOC|034897666‏
996 ‎‡2 SUDOC|074173219‏
996 ‎‡2 NDL|01062490‏
996 ‎‡2 ISNI|0000000436786172‏
996 ‎‡2 NKC|ola2008452246‏
996 ‎‡2 LC|n 82038138‏
996 ‎‡2 NTA|129988324‏
996 ‎‡2 DNB|124707785‏
996 ‎‡2 CAOONL|ncf10126038‏
996 ‎‡2 ISNI|0000000066406776‏
996 ‎‡2 ISNI|0000000068851398‏
996 ‎‡2 LC|n 2021058288‏
996 ‎‡2 J9U|987007345144105171‏
996 ‎‡2 ISNI|0000000124105163‏
996 ‎‡2 LC|nr2004011078‏
996 ‎‡2 ISNI|0000000082347825‏
996 ‎‡2 SUDOC|15224316X‏
996 ‎‡2 N6I|vtls000278946‏
996 ‎‡2 ISNI|0000000108562794‏
996 ‎‡2 LC|no2022037210‏
996 ‎‡2 NUKAT|n 99004687‏
996 ‎‡2 J9U|987007280405905171‏
996 ‎‡2 LC|n 77007202‏
996 ‎‡2 J9U|987007605399205171‏
996 ‎‡2 BNF|10731570‏
996 ‎‡2 J9U|987007331924605171‏
996 ‎‡2 LC|n 79063668‏
996 ‎‡2 LC|nb2014029280‏
996 ‎‡2 J9U|987007458823005171‏
996 ‎‡2 LC|nr 90022382‏
996 ‎‡2 CAOONL|ncf11735043‏
996 ‎‡2 LC|n 2003047881‏
996 ‎‡2 LC|n 2011026541‏
996 ‎‡2 DNB|100421601‏
996 ‎‡2 ISNI|0000000044975580‏
996 ‎‡2 LC|n 2007068129‏
996 ‎‡2 LC|n 95035082‏
996 ‎‡2 ISNI|0000000077364372‏
996 ‎‡2 SUDOC|164131639‏
996 ‎‡2 LC|nr 90022499‏
996 ‎‡2 SUDOC|229958990‏
996 ‎‡2 RERO|A014157693‏
996 ‎‡2 BNF|15098517‏
996 ‎‡2 CAOONL|ncf10031431‏
996 ‎‡2 SUDOC|12209994X‏
996 ‎‡2 LIH|LNB:B_n_2_m_;=B_v_‏
996 ‎‡2 LC|no2005110134‏
996 ‎‡2 N6I|vtls001323625‏
996 ‎‡2 LC|n 2019023835‏
996 ‎‡2 DNB|117561657‏
996 ‎‡2 LC|nr 88010187‏
996 ‎‡2 ISNI|0000000384088427‏
996 ‎‡2 BIBSYS|10043686‏
996 ‎‡2 LC|no2001071037‏
996 ‎‡2 SZ|120419505‏
996 ‎‡2 LC|n 91055087‏
996 ‎‡2 ISNI|0000000045060841‏
996 ‎‡2 PLWABN|9812830218305606‏
996 ‎‡2 LC|n 82096558‏
996 ‎‡2 LC|n 88614052‏
996 ‎‡2 NTA|073244422‏
996 ‎‡2 BIBSYS|9015365‏
996 ‎‡2 J9U|987007353110405171‏
996 ‎‡2 LC|n 2014187440‏
996 ‎‡2 NTA|069411042‏
996 ‎‡2 ISNI|0000000080198782‏
996 ‎‡2 LC|n 87803041‏
996 ‎‡2 PLWABN|9810643849205606‏
996 ‎‡2 NUKAT|n 2020149594‏
996 ‎‡2 BIBSYS|90565276‏
996 ‎‡2 ISNI|000000007450064X‏
996 ‎‡2 ISNI|0000000082563480‏
996 ‎‡2 ISNI|0000000110438207‏
996 ‎‡2 ISNI|000000004503343X‏
996 ‎‡2 LC|nr 90022514‏
996 ‎‡2 NDL|00550675‏
996 ‎‡2 RERO|A022927148‏
996 ‎‡2 SUDOC|060611901‏
996 ‎‡2 LC|n 79110808‏
996 ‎‡2 NLA|000035316408‏
996 ‎‡2 LC|no2022104420‏
996 ‎‡2 PLWABN|9810628063005606‏
996 ‎‡2 LC|n 89225747‏
996 ‎‡2 NTA|072417978‏
996 ‎‡2 JPG|500225742‏
996 ‎‡2 LC|nb2009006941‏
996 ‎‡2 LC|no2005052944‏
996 ‎‡2 NUKAT|n 2021032801‏
996 ‎‡2 SUDOC|185101992‏
996 ‎‡2 ISNI|0000000063360880‏
996 ‎‡2 NTA|163296057‏
996 ‎‡2 BNF|12560143‏
996 ‎‡2 BNF|16976946‏
996 ‎‡2 B2Q|0000678262‏
996 ‎‡2 ISNI|0000000122817239‏
996 ‎‡2 LC|n 97077309‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏